Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Bianchini F, Weiderpass E, Kyrtopoulos S, Souliotis VL, Henry-Amar M, Wild CP, Boffetta P.
PMID: 23888989
Biomarkers. 1996;1(4):226-31. doi: 10.3109/13547509609079362.

Abstract The aim of the present study was to assess the relationship between dose of the methylating agent procarbazine (PCZ), DNA methylation adduct formation andresponse to chemotherapy treatment in 23 Hodgkin's disease patients receiving MOPP/ABV combination therapy. The DNA...

Cite
Bianchini F, Weiderpass E, Kyrtopoulos S, et al. Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers. 1996;1(4):226-31doi: 10.3109/13547509609079362.
Bianchini, F., Weiderpass, E., Kyrtopoulos, S., Souliotis, V. L., Henry-Amar, M., Wild, C. P., & Boffetta, P. (1996). Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 1(4), 226-31. https://doi.org/10.3109/13547509609079362
Bianchini, F, et al. "Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine." Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals vol. 1,4 (1996): 226-31. doi: https://doi.org/10.3109/13547509609079362
Bianchini F, Weiderpass E, Kyrtopoulos S, Souliotis VL, Henry-Amar M, Wild CP, Boffetta P. Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers. 1996;1(4):226-31. doi: 10.3109/13547509609079362. PMID: 23888989.
Copy Download .nbib Format: NLM
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.

Cancer

Nerich V, Guyeux C, Henry-Amar M, Couturier R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Sibon D, Ysebaert L, Nicolas-Virelizier E, Broussais-Guillaumot F, Damaj GL, Jais JP, Salles G, Woronoff-Lemsi M, Mounier N.
PMID: 34605020
Cancer. 2021 Oct 04; doi: 10.1002/cncr.33938. Epub 2021 Oct 04.

BACKGROUND: No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in...

Cite
Nerich V, Guyeux C, Henry-Amar M, et al. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2021;doi: 10.1002/cncr.33938.
Nerich, V., Guyeux, C., Henry-Amar, M., Couturier, R., Thieblemont, C., Ribrag, V., Tilly, H., Haioun, C., Casasnovas, R. O., Morschhauser, F., Feugier, P., Sibon, D., Ysebaert, L., Nicolas-Virelizier, E., Broussais-Guillaumot, F., Damaj, G. L., Jais, J. P., Salles, G., Woronoff-Lemsi, M., & Mounier, N. (2021). Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer, . https://doi.org/10.1002/cncr.33938
Nerich, Virginie, et al. "Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33938
Nerich V, Guyeux C, Henry-Amar M, Couturier R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Sibon D, Ysebaert L, Nicolas-Virelizier E, Broussais-Guillaumot F, Damaj GL, Jais JP, Salles G, Woronoff-Lemsi M, Mounier N. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2021 Oct 04; doi: 10.1002/cncr.33938. Epub 2021 Oct 04. PMID: 34605020.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries